Beta-2 Glycoprotein 1 Antibodies, IgG and IgM

Casandra

Casandra Test Code AR37403Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 0050321CPT Code 86146

Beta-2 Glycoprotein 1 Antibodies, IgG and IgM

Also known as: B2GPI PAN

Clinical Use

Order Test

Use

The test is an acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. It should be ordered with the Lupus Anticoagulant Reflex Panel and Cardiolipin Antibodies tests. It is also useful in estimating the risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus (SLE). The persistent presence of IgG and/or IgM beta 2 glycoprotein I (B2GPI) antibodies is a laboratory criterion for the diagnosis of APS. Persistence is defined as moderate or high levels detected in at least two specimens drawn at least 12 weeks apart.

Special Instructions

Order with Lupus Anticoagulant Reflex Panel and Cardiolipin Antibodies, IgG and IgM tests. Ensure proper sample collection and processing by maintaining appropriate test conditions.

Limitations

Results greater than 20 SGU (IgG) and/or SMU (IgM) are considered positive based on the cutoff values established for this test. However, international reference materials and consensus units for anti-B2GPI antibodies have not been established, meaning results can be variable between different commercial immunoassays and cannot be compared directly. Low positive and negative results should be interpreted in the context of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests.

Test Details

FDA Approved